Cargando…
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
BACKGROUND: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidan...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520356/ https://www.ncbi.nlm.nih.gov/pubmed/28728605 http://dx.doi.org/10.1186/s12916-017-0902-9 |